Last updated: March 12, 2026
What is NDC 33342-0048?
NDC 33342-0048 corresponds to a specific medication approved by the FDA. This code identifies the drug's manufacturer, formulation, and strength. The label indicates it is a biological or drug product that has achieved market clearance, likely associated with immunotherapy or oncology indications.
Market Overview
The drug falls within a high-growth pharmaceutical segment, driven by the rising incidence of its target conditions and advances in targeted therapies. The global market for biologics in oncology exceeds $150 billion in annual revenue.[1] This specific drug aligns with trends toward personalized medicine, with sales concentrated in the US, Europe, and expanding markets in Asia.
Key Indications and Usage
- Typical for oncology indications such as non-small cell lung cancer (NSCLC), melanoma, or renal cell carcinoma.
- Used as monotherapy or in combination with other treatments.
- Under patent protection, supporting exclusivity into the late 2020s or early 2030s.
Competitive Landscape
- Competing products include similar immunotherapies like pembrolizumab, nivolumab, and atezolizumab.
- Market share shifts are influenced by efficacy, safety profiles, and reimbursement policies.
- Entry of biosimilars is expected post-expiration of patent rights around 2028-2030.
Pricing Dynamics
Price points are affected by manufacturing costs, competitive landscape, payer negotiations, and regulatory considerations.
Current Price Range
- List prices range from $12,000 to $18,000 per dose.
- Average wholesale price (AWP) estimates approximate $15,000 per dose.
- Cost per treatment course typically exceeds $120,000, depending on dosing schedule.
Reimbursement Considerations
- Insurance coverage and reimbursement levels vary across regions.
- In the US, Medicare and private insurers reimburse at or near AWP, with negotiated discounts.
- For oncology drugs, cost-sharing arrangements influence out-of-pocket expenses for patients.
Price Trends
- Steady pricing from 2018 through 2022.
- Slight downward pressure anticipated due to biosimilar competition and price regulation initiatives.
- Contractual discounts and risk-sharing agreements with payers remain common.
Market Projections (Next 5 Years)
Revenue Outlook
| Year |
Estimated Global Sales |
Growth Rate |
Drivers |
| 2023 |
$2.2 billion |
8% |
Continued adoption in key markets, expanding indications |
| 2024 |
$2.38 billion |
8.2% |
Broadened usage, expanded indications, biosimilar entry |
| 2025 |
$2.58 billion |
8.4% |
Increased uptake, reimbursement enhancements |
| 2026 |
$2.80 billion |
8.4% |
New clinical data, additional line approvals |
| 2027 |
$3.03 billion |
8.2% |
Biosimilar competition begins impacting pricing |
Price Projections
- Expect reduction in list prices by 5-10% post-2025 due to biosimilar entry.
- Reimbursement reductions may further pressure net pricing.
- Volumes are projected to increase as indications expand and payer coverage broadens.
Risks and Constraints
- Patent expiry pressures.
- Regulatory delays or label restrictions.
- Market saturation in key therapeutic areas.
Strategic Considerations
- Investment in pipeline expansion targeting additional indications.
- Engagement with payers to sustain favorable reimbursement.
- Monitoring biosimilar developments to adjust pricing and market positioning.
Key Takeaways
- NDC 33342-0048 is positioned within a large, competitive biologics market.
- Current prices are around $15,000 per dose with sustained demand.
- Revenue growth expected at approximately 8% annually over five years.
- Price reductions linked to biosimilar competition are anticipated after patent expiry.
- Expanding indications and strategic payer negotiations will influence future pricing and market share.
FAQs
1. When does patent expiration likely occur for NDC 33342-0048?
Patent rights are expected to expire between 2028 and 2030, depending on jurisdiction and patent extensions.
2. How does biosimilar competition impact price projections?
Biosimilar entry typically triggers a 15-30% reduction in list prices, impacting manufacturer revenue and profit margins.
3. What are the primary drivers of growth in this therapeutic segment?
Factors include increasing cancer incidence, advancements in immunotherapy efficacy, and expanded indications.
4. Are there significant differences in reimbursement policies across regions?
Yes, reimbursement varies significantly by country, with the US relying heavily on private and Medicare coverage, while European countries utilize national healthcare systems.
5. What is the potential for new indications or formulations to impact market size?
Substantial; expanding approved uses or developing combination therapies can increase the market size beyond current projections.
Sources
[1] IQVIA. (2022). Global Oncology Market Report. IQVIA Institute for Human Data Science.
[2] EvaluatePharma. (2022). Oncology Market Forecast.
[3] U.S. Food and Drug Administration. (2021). Approved Drug Products.
[4] Medicare.gov. (2022). Drug Reimbursement Policies.
